Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | F7 | P08709 | 3/20 | 0.46 |
| ▸ | F3 | P13726 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419343 | 1.00 | PTGS1 (0.50) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL15808482 | 0.90 | ALDH1A1 (0.51) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL12357092 | 0.90 | ALDH1A1 (0.51) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL2254035 | 0.89 | ALDH1A1 (0.51) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL2254029 | 0.89 | ALDH1A1 (0.51) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL18417710 | 0.89 | ALDH1A1 (0.51) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL3424298 | 0.88 | ALDH1A1 (0.54) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL3424303 | 0.88 | ALDH1A1 (0.54) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL18944651 | 0.86 | ALDH1A1 (0.53) | PTGS1ALDH1A1CYP19A1MAPTPPARG | |
| SCHEMBL18920278 | 0.81 | PTGS1 (0.51) | PTGS1ALDH1A1CYP19A1MAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029368-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS | 2017-02-02 | — | — | US | disclosed |
| US-20170029368-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS | 2017-02-02 | — | — | US | disclosed |
| US-20170029368-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS | 2017-02-02 | — | — | US | disclosed |
| EP-2313090-B1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2016-03-30 | — | — | EP | disclosed |
| EP-2313090-B1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2016-03-30 | — | — | EP | disclosed |
| US-20140316002-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-10-23 | — | — | US | disclosed |
| US-20140316002-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-10-23 | — | — | US | disclosed |
| US-20140316002-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-10-23 | — | — | US | disclosed |
| US-8759558-B2 | Sulphur containing lipids for use as food supplement or as medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-24 | — | — | US | disclosed |
| US-8759558-B2 | Sulphur containing lipids for use as food supplement or as medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-24 | — | — | US | disclosed |
| US-8759558-B2 | Sulphur containing lipids for use as food supplement or as medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-24 | — | — | US | disclosed |
| US-20110190395-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-08-04 | — | — | US | disclosed |
| US-20110190395-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-08-04 | — | — | US | disclosed |
| WO-2010008299-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010008299-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140316002-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | SGMS2, SGMS1, ACSS2 | PTGS1 960/4885ALDH1A1 514/4885CYP19A1 2818/4885 |
| US-20170029368-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | SGMS2, SGMS1, FABP2 | PTGS1 1167/4885ALDH1A1 472/4885CYP19A1 3183/4885 |
| US-20110190395-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | SGMS2, SGMS1, ACSS2 | PTGS1 960/4885ALDH1A1 514/4885CYP19A1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.